Savara Overview

  • Founded
  • 2007
Founded
  • Status
  • Public
  • Employees
  • 27
Employees
  • Stock Symbol
  • SVRA
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $1.77
  • (As of Friday Closing)

Savara General Information

Description

Savara Inc is a pharmaceutical company. The company develops novel therapies for the treatment of serious or life-threatening rare respiratory diseases. It offers products such as AeroVanc, for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, for the treatment of autoimmune pulmonary alveolar proteinosis and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. All the business activity of the firm functions through the region of the United States.

Contact Information

Website
www.savarapharma.com
Formerly Known As
Savara Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 6836 Bee Cave Road, Building 3
  • Suite 200
  • Austin, TX 78746
  • United States
+1 (512) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Savara Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.77 $1.83 $1.00 - $3.58 $201M 114M 2.01M -$0.70

Savara Financials Summary

In Thousands,
USD 		TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 175,464 (6,883) 146,739 169,302
Revenue 257 257 0 0
EBITDA (41,941) (47,440) (77,093) (68,058)
Net Income (44,410) (49,615) (78,173) (61,516)
Total Assets 207,630 97,745 136,203 152,287
Total Debt 25,383 25,283 25,552 24,571
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Savara Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Savara Inc is a pharmaceutical company. The company develops novel therapies for the treatment of serious or life-threat
Biotechnology
Austin, TX
27 As of 2020
00000
000000000 00000

0000 000

mco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volup
0000 000000000
Austin, TX
00 As of 0000
000.00
0000000000 000.00

0000000

ure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000 000000000
Stevenage, United Kingdom
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Savara Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lung Therapeutics Venture Capital-Backed Austin, TX 00 000.00 0000000000 000.00
0000000 Venture Capital-Backed Stevenage, United Kingdom 00 00000 00000000000 00000
0000000000 0000000 Venture Capital-Backed Brighton, United Kingdom 00 000.00 00000000000 000.00
000000000 Corporation Southampton, United Kingdom 00 00000 000000000 00000
000000 000000 Accelerator/Incubator Backed Morristown, NJ 0 00.000 0000000000 00.000
You’re viewing 5 of 14 competitors. Get the full list »

Savara Executive Team (13)

Name Title Board Seat Contact Info
David Lowrance Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
John Lord Ph.D Senior Vice President, Head of R&D & Head of Site
Anne Erickson Senior Vice President & Chief of Staff
Badrul Chowdhury Ph.D Chief Medical Officer
You’re viewing 4 of 13 executive team members. Get the full list »

Savara Board Members (8)

Name Representing Role Since
David Ramsay Self Board Member 000 0000
Joseph McCracken Self Board Member 000 0000
Matthew Pauls JD Self Chairman & Chief Executive Officer 000 0000
Nevan Elam JD Self Board Member 000 0000
Richard Hawkins Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Savara Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Savara Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 000000 (00 25-Jul-2018 000000000 00000 00 Buildings and Property 000000 0000000
0000 000000000000 27-Apr-2017 000000000000000000 00000 Pharmaceuticals 000000 0000000
Serendex Pharmaceuticals 13-May-2016 Corporate Asset Purchase 000.00 Buildings and Property 000000 0000000
To view Savara’s complete investments and acquisitions history, request access »

Savara Subsidiaries (1)

Company Name Industry Location Founded
000000 Pharmaceuticals Austin, TX 0000
To view Savara’s complete subsidiaries history, request access »